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Background: This meta-analysis aimed to evaluate the efficiency and safety of combined intravenous and topical
methods of application versus single intravenous of tranexamic acid in primary total knee and hip arthroplasty.
Methods: A systematic search was carried out in MEDLINE (from 1966 to 25 September 2016), PubMed (from 1966
to 25 September 2016), Embase (from 1980 to 25 September 2016), ScienceDirect (from 1985 to 25 September
2016) and the Cochrane Library. Only high-quality randomised controlled trials (RCT) were identified. Two authors
independently performed data extraction and quality assessment of included studies. Meta-analysis was conducted
using Review Manager 5.1 software.
Results: Six RCTs that included 687 patients met the inclusion criteria. The present meta-analysis indicated that
there were significant differences in terms of total blood loss (MD = −193.59, 95% CI −338.06 to −49.13, P = 0.009),
transfusion rate (RD = −0.07, 95% CI −0.12 to −0.03, P = 0.001), haemoglobin decline (MD = −0.51, 95% CI −0.83
to −0.18, P = 0.01) and length of stay (MD = −0.20, 95% CI −0.38 to −0.02, P = 0.03) between groups.
Conclusions: Combined administration of tranexamic acid (TXA) in patients with total knee and hip arthroplasty
was associated with significantly reduced total blood loss, transfusion requirements, postoperative haemoglobin
decline and length of stay compared to single application alone but was not associated with prolonged operation
time. Moreover, no adverse effects, such as superficial infection, deep vein thrombus (DVT) or pulmonary embolism
(PE), were associated with TXA. We suggest that combined administration of TXA demonstrated excellent clinical
efficacy and safety in patients with total knee and hip arthroplasty. More importantly, well-designed studies with
larger sample size are needed to provide further reliable evidence for the combined use of TXA.
Keywords: Total hip replacement, Total knee replacement, Tranexamic acid, Meta-analysis, Total knee and hip
arthroplasty, Blood loss* Correspondence: rose_030201@163.com
5Department of Radiotherapy, Cancer hospital of Ji Lin, Changchun, Ji Lin,
China
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Li et al. Journal of Orthopaedic Surgery and Research  (2017) 12:22 Page 2 of 10Background
Total knee arthroplasty and hip arthroplasty (TKA and
THA) are the most commonly employed orthopaedic
operations to treat degenerative arthritis and traumatic
conditions such as displaced femoral neck fractures. It
has been estimated that more than 700,000 TKAs are
performed annually in the USA. However, substantial
perioperative blood loss has been associated with sys-
temic complications, especially in elderly individuals
[1, 2]. Many methods have been employed to attempt
to manage blood loss including tourniquet applica-
tion, blood transfusion, administration of haemostatic
agents and autologous donation [3]. Allogenic blood
transfusion may increase the risk of adverse events,
such as virus infections, immunologically mediated
diseases and cardiovascular dysfunction, potentially
resulting in life-threatening effects on patients and an
added financial burden on the patients [4].
Recently, the use of tranexamic acid (TXA) in total knee
and hip arthroplasty has become popular among the ortho-
paedic surgeons. TXA is a synthetic analogue of an amino
acid with biological activity which can inhibit plasminogen
from dissolving clots [5]. In previous studies, combined
intravenous and topical applications of TXA have been re-
ported to be associated with reduced perioperative blood
loss and transfusion units [6]. Despite this research, the
lack of large published studies and small sample sizes
makes it unclear whether the combined application of
TXA is superior to single intravenous application. There-
fore, we performed a meta-analysis to evaluate the effi-
ciency and safety of combined intravenous and topical
methods of application versus single intravenous of tranex-
amic acid in primary total knee and hip arthroplasty.
Methods
Search strategy
Studies were considered for inclusion if they met the fol-
lowing criteria: (1) published randomised control trials
(RCTs); (2) included a patient population that underwent
total knee or hip arthroplasty, with an experimental
group that received combined intravenous and topical
application of TXA and a control group that received a
single application of TXA; (3) reported surgical outcomes
including haemoglobin decline or postoperative haemo-
globin level, total blood loss, drainage volume, transfusion
requirements, length of stay and operation time as well as
surgery-related adverse effects, such as wound infection,
deep vein thrombosis (DVT) and pulmonary embolism
(PE). Studies were excluded from the present meta-
analysis if they included incomplete data. All analyses
were based on previous published studies; thus, no ethical
approval and patient consent are required.
Potentially relevant studies were identified from elec-
tronic databases including MEDLINE (from 1966 to 25September 2016), PubMed (from 1966 to 25 September
2016), Embase (from 1980 to 25 September 2016),
ScienceDirect (from 1985 to 25 September 2016) and
the Cochrane Library. The following keywords were
used on combination with Boolean operators AND or
OR: “total knee replacement OR arthroplasty”, “total hip
replacement OR arthroplasty” and “tranexamic acid”,
“blood loss” or “blood transfusion”. The bibliographies
of retrieved trials and other relevant publications were
cross-referenced to identify additional articles. The
search process was performed as presented in Fig. 1.
Date extraction
Two reviewers independently scanned the abstracts of
the potentially included studies. Subsequently, the full
text of the studies that met the inclusion criteria was
screened, and a final decision was made. Disagreement
was resolved by consulting a senior reviewer. Two of the
authors independently extracted data from the included
studies. Corresponding authors were consulted for de-
tails if the data were incomplete. The following data
were extracted and recorded in a spreadsheet: first au-
thor names, publication year, baseline characteristics,
intervention procedures, sample size, transfusion trigger
and outcome parameters. Other relevant data were also
extracted from individual studies. Primary outcomes
were total blood, haemoglobin decline and transfusion
requirements. Secondary outcomes were length of stay,
operation time and TXA-related adverse effects, such as
superficial infection, DVT or PE.
Quality assessment
A quality assessment of each randomised trial was per-
formed by two reviewers based on the Cochrane Handbook
for Systematic Reviews of Interventions. Disagreement was
resolved by consulting a senior reviewer. We created a “risk
of bias” table that included the following elements: random
sequence generation, allocation concealment, blinding,
incomplete outcome data, free of selective reporting
and other bias.
Data analysis and statistical methods
Pooling of data was carried out using RevMan 5.1 (The
Cochrane Collaboration, Oxford, UK). Statistical hetero-
geneity was assessed based on the value of P and I2
values and using standard chi-square tests. When I2 ≥
50% or P < 0.1, significant heterogeneity was indicated and
a random-effects model was applied for meta-analysis.
Otherwise, a fixed-effects model was used. Sensitivity
analysis is conducted to find the source if possible under
significant heterogeneity. Dichotomous outcomes were
expressed as risk differences (RDs) with 95% confidence in-
tervals (CIs). For continuous outcomes, mean differences
(MDs) and 95% confidence intervals (CIs) were calculated.
Fig. 1 Search results and the selection procedure
Table 1 Cohort characteristics



















Jain 2016 [12] 59/60 68.3/70.0 39/36 TKA E:pre-op.15 mg/kg i.v. + post-op.
10 mg/kg i.v. + 2 g topical injection
Aspirin, 75 mg HB less than
7 g/dL
NS
C:pre-op.15 mg/kg i.v. + post-op.
10 mg/kg i.v






Wu 2016 [10] 42/42 60.1/59.5 19/21 Reversion
THA




Song 2016 [9] 50/50 70.8/69.2 43/44 TKA E: 1.5 g topical injection +10 mg/kg i.v.
C:E:pre-op.10 mg/kg i.v. + post-op.10 mg/kg
Not performed HB less than
8 g/dL
1 month
E experiment group, C control group, i.v. intravenous injection, LMWH low-molecular-weight heparin, HB haemoglobin, pre-op preoperative, post-op postoperative,
NS not stated
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Table 2 Methodological quality of the randomized controlled trials
Table 3 Risk of bias
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Fig. 2 Forest plot diagram showing effect of combination TXA on total blood loss
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Search result
A total of 189 studies were identified through the initial
search. By scanning the abstracts, 183 reports that did
not meet inclusion criteria were excluded from the
meta-analysis and no grey studies were included. Finally,
six randomised control trials (RCTs) [7–12] that had
been published between 2014 and 2016 were used for
this meta-analysis. These studies included 343 patients
in experimental groups and 344 patients in control
groups. The experimental groups received combined
intravenous and topical TXA, while control groups re-
ceived single intravenous TXA. Sample sizes ranged
from 60–184 patients. Doses of TXA in each study are
summarised in Table 1 as well as the demographic char-
acteristics of the participants. The primary outcomes
were total blood loss, haemoglobin decline, transfusion
requirement and drainage volume. The secondary out-
comes were operation time, length of stay and adverse
side effects. The duration of follow-up ranged from
1 month to 2 years.Fig. 3 Forest plot diagram showing effect of combination TXA on transfusRisk of bias assessment
The Cochrane Handbook for Systematic Review of In-
terventions was consulted to assess the quality of the
trials. All RCTs provided clear inclusion and exclusion
criteria and described their randomization method-
ology, and three studies [8, 9, 12] described the use
of computer-generated randomization. Five studies
[7–11] reported allocation concealment by closed en-
velope or other techniques. Double blinding was re-
ported in five of the trials [7–10, 12]; however, only
one study [8] had attempted to blind assessors.
Intention-to-treat analysis was not performed in any
of the RCTs; therefore, there was a potential risk of
type II statistical errors occurring. No unclear bias
was identified, due to incomplete outcome data or se-
lective outcome reporting. The methodological quality
assessment is summarised in Table 2. Each risk of
bias item is presented as a percentage across all the
included studies, which indicates the proportion of
the different levels of risk of bias for each item
(Table 3).ion rate
Fig. 4 Forest plot diagram showing effect of combination TXA on haemoglobin decline
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Total blood loss
Six articles [7–12] reported the outcomes of total blood
loss following operation. There was significant hetero-
geneity among the studies (χ2 = 93.58, df = 5, I2 = 95%,
P < 0.00001); therefore, a random-effects model was
used. Pooled results demonstrated that total blood
loss in control groups was significantly higher than in
experimental groups (MD = −193.59, 95% CI −338.06
to −49.13, P = 0.009; Fig. 2).Transfusion rate
Transfusion rates were reported in five studies [7, 8, 10–
12]. No significant heterogeneity among these studies
was found; therefore, a fixed-effects model was ap-
plied (χ2 = 5.42, df = 4, I2 = 26%, P = 0.25). There was a
significant difference between the two groups in
transfusion rate (RD = −0.07, 95% CI −0.12 to −0.03,
P = 0.001; Fig. 3).Haemoglobin decline
Four studies [7, 9, 10, 12] reported the outcomes of
haemoglobin decline following operation. There was sig-
nificant heterogeneity among these studies (χ2 = 19.30,
df = 3, I2 = 84%, P = 0.0002); therefore, a random-effects
model was used. Pooled results demonstrated that
haemoglobin decline in control groups was significantlyFig. 5 Forest plot diagram showing effect of combination TXA on drainagehigher than in experimental groups (MD = −0.51, 95%
CI −0.83 to −0.18, P = 0.01; Fig. 4).
Drainage volume
Drainage volume was provided in three studies [7, 9,
10]. Significant heterogeneity among these studies was
found; therefore, a random-effects model was used
(χ2 = 54.36, df = 2, I2 = 96%, P < 0.00001). There was no
significance between the two groups in drainage volume
(MD= −90.69, 95% CI −197.72 to 16.34, P = 0.10; Fig. 5).
Operation time
Operation time was reported in five studies [7–11].
There was no significant heterogeneity among the
pooled data; therefore, a fixed-effects model was used
(χ2 = 1.95, df = 4, I2 = 0%, P = 0.74). There was no sig-
nificance between the two groups in operation time.
(MD = 1.46, 95% CI −0.40 to 3.33, P = 0.12; Fig. 6).
Length of hospital stay
Four studies reported the length of hospital stay between
groups [7, 8, 10, 11]. No significant heterogeneity was
identified in the pooled results; therefore, a fixed-effects
model was used (χ2 = 3.27, df = 2, I2 = 8%, P = 0.35).
There was no significant difference between the two
groups in length of hospital stay (LOS). (MD = −0.20,
95% CI −0.38 to −0.02, P = 0.03; Fig. 7).volume
Fig. 6 Forest plot diagram showing effect of combination TXA on operation time
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Superficial infection incidence was reported in five stud-
ies [7–11]. No significant heterogeneity among these
studies was found; therefore, a fixed-effects model was
used (χ2 = 0.69, df = 4, I2 = 0%, P = 0.95). There was no
significant difference between the two groups in the inci-
dence of superficial infection (RD = 0.00, 95% CI −0.02
to 0.02, P = 1.00; Fig. 8).
Deep vein thrombosis
Six articles [7–12] reported the incidence of DVT fol-
lowing joint replacement. A fixed-effects model was
used due to the low-significant heterogeneity among
these studies (χ2 = 1.97, df = 5, I2 = 0%, P = 0.85). No
significant difference was found between the groups
(RD = −0.00, 95% CI −0.02 to 0.02, P = 0.79; Fig. 9).
Discussion
Substantial studies have assessed the efficiency and
safety of TXA by various routines in total knee and hip
arthroplasty. However, intravenous combined topical use
of TXA was seldom studies. Therefore, this is the first
meta-analysis to evaluate the efficiency and safety of
combined use of intravenous and topical versus single
intravenous TXA in primary total knee and hipFig. 7 Forest plot diagram showing effect of combination TXA on length oarthroplasty. The most important finding of the meta-
analysis was that combined application of intravenous
and topical tranexamic acid in patients with TKA and
THA was associated with significantly reduced total
blood loss, postoperative haemoglobin decline and trans-
fusion requirements compared to single intravenous ap-
plication where no increased risk of the incidence of
infection, DVT or PE was identified. More interest-
ingly, our finding indicated that there is a shortened
length of stay in combined groups.
Although the overall methodological quality of the six
selected studies was relatively high, some methodological
weaknesses existed which would have affected their re-
sults. For example, the sample size of all studies was
relatively small and the statistical efficacy could be im-
proved by including more studies with larger sample
sizes as well as long-term follow-ups with patients.
Three studies did not clarify their randomization
methods, and one study did not indicate allocation
concealment. We attempted to find the source of het-
erogeneity for total blood loss; however, it still
existed. Publication bias of the meta-analysis also in-
fluenced results. These shortcomings should be taken
into consideration when analysing the results of this
meta-analysis.f stay
Fig. 8 Forest plot diagram showing effect of combination TXA on risk of superficial infection
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sis by reversibly blocking the lysine-binding sites of plas-
minogen. This method is commonly used in orthopaedic
surgery to decrease intraoperative blood loss and transfu-
sion amounts. TXA can be applied by various routes in-
cluding intravenous, intraarticular, oral and intramuscular.
For patients undergoing TKA, the best suitable method
for rapidly increasing and maintaining the therapeutic
concentration of TXA is by the intravenous route. Topical
application of TXA has many conceptual and realistic ad-
vantages. Firstly, TXA inhibits local activation of fibrinoly-
sis as well as systemic activation from local mediators
after tourniquet release [13]. Additionally, a higher con-
centration of local TXA in the knee joint should result in
greater thrombus formation and a lower time to vascular
occlusion [14]. Further, topical TXA has very low systemic
absorption. This meta-analysis indicated that combined
application of TXA was associated with significantly re-
duced total blood loss compared with a single application
of TXA. Because there was significant heterogeneityFig. 9 Forest plot diagram showing effect of combination TXA on risk of damong the studies, we performed sensitivity analysis to ex-
cluded studies whose sample size was small. However, sig-
nificant heterogeneity still existed (Fig. 10).
Substantial numbers of previous studies have reported
total blood loss in patients undergoing TKA and THA;
for instance, TKA without antifibrinolytics was associ-
ated with blood loss ranging from 761 to 1784 ml
[15–18] and 7.7 to 18.93% [19–22] of these patients
needed transfusion to relieve anaemia. However, transfu-
sion was considered undesirable due to its associated risks
with adverse reactions. It has been frequently identified
that when either systemic or topical administration of
TXA was administrated, transfusion was required less fre-
quently. The current meta-analysis showed that combined
application of TXA was associated with a further signifi-
cant reduction in transfusion requirements and haemoglo-
bin decline compared to single application in patients
with total knee and hip replacement.
Long periods of bedridden patients and extensive op-
eration times increase the expenses associated witheep vein thrombosis
Fig. 10 Sensitivity analysis on total blood loss
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hypostatic pneumonia, deep vein thrombosis and
pulmonary embolism are associated with increased mor-
bidity and mortality [19]. Early weight-bearing and re-
habilitation have been shown to contribute to better
functional outcomes following knee and hip arthroplasty.
This meta-analysis indicated that combined administra-
tion of TXA was associated with shortened bedridden
durations following total knee and hip arthroplasty com-
pared to single application. We speculate that the results
may be caused by reduced blood loss and transfusion re-
quirements which are another important finding.
Infection is relatively rare after TKA but can be devas-
tating in terms of morbidity and associated costs. This
meta-analysis showed that there was no significant differ-
ence in the incidence of infection, which was 4/284 in the
experimental groups and 4/284 in the control groups. The
overall infection incidence was 1.4%, which is in accord-
ance with previous studies which reported incidences ran-
ging between 1 and 3% [23]. High-quality trials with larger
sample sizes are required to further explore the correl-
ation between infection and application of TXA.
DVT has been identified as a common complication
that may develop into PE and even result in death fol-
lowing major orthopaedic surgery. Most participants re-
ceived routine prophylactic antithrombotic therapy.
Previous studies have reported that there was a higher
risk of developing DVT and PE when TXA was utilised
[24]. Perhaps this finding occurred because TXA, an
antifibrinolytic agent, has the tendency to increase the
risk of clotting. Therefore, there was a possibility that
combined application of TXA would be more likely to
result in the formation of a thrombus. However, no sig-
nificant difference was found between the groups in
terms of the incidence of DVT or PE. As identified for
the other factors, further large-scale trials are needed to
confirm the observed outcomes.
Several potential limitations that should be noted: (1)
Only six RCTs were included, and the sample size was
relatively small. (2) Some outcome parameters such as
the visual pain score (VAS) and range of motion (ROM)were not fully described and could not be included in
the meta-analysis. (3) Because of the limited number of
included studies, subgroup analyses were not performed
for some outcomes; therefore, we could not determine
the source of heterogeneity. (4) Short-term follow-up
may lead to underestimation of complications. (5)
Publication bias is an inherent weakness that exists in
all meta-analyses.
Conclusions
Combined administration of TXA in patients with total
knee and hip arthroplasty was associated with signifi-
cantly reduced total blood loss, transfusion require-
ments, postoperative haemoglobin decline and length of
stay compared to single application alone but was not
associated with prolonged operation time. Moreover, no
adverse effects, such as superficial infection, DVT or PE,
were associated with TXA. We suggest that combined
administration of TXA demonstrated excellent clinical
efficacy and safety in patients with total knee and hip
arthroplasty. More importantly, well-designed studies
with larger sample size are needed to provide further re-
liable evidence for the combined use of TXA.
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